New hope for Hard-to-Treat ovarian cancer: experimental drug lorigerlimab enters phase 2 trial
NCT ID NCT06730347
First seen Nov 01, 2025 · Last updated May 08, 2026 · Updated 29 times
Summary
This study tests an experimental drug called lorigerlimab in about 60 people with advanced ovarian or other gynecologic cancers that no longer respond to standard chemotherapy. Participants receive the drug by IV every 3 weeks. The goal is to see if the drug can shrink tumors and to monitor side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PLATINUM-RESISTANT FALLOPIAN TUBE CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Gangnam Severance Hospital
RECRUITINGSeoul, 06273, South Korea
Contact
Contact
-
Korea University Guro Hospital
RECRUITINGSeoul, 08308, South Korea
Contact
Contact
-
Mays Clinic
RECRUITINGHouston, Texas, 77030, United States
Contact
Contact
-
McGill University
RECRUITINGMontreal, Quebec, H4A3J1, Canada
Contact
Contact
-
National Cancer Center
RECRUITINGGoyang-si, Gyeonggi-do, 410-763, South Korea
Contact
Contact
-
Ochsner MD Anderson Cancer Center
RECRUITINGNew Orleans, Louisiana, 70115, United States
Contact
Contact
-
Princess Margaret Cancer Center
RECRUITINGToronto, Ontario, M5G 2M9, Canada
Contact
Contact
-
START Midwest
RECRUITINGGrand Rapids, Michigan, 49546, United States
Contact
Contact
-
START San Antonio
RECRUITINGSan Antonio, Texas, 78229, United States
Contact
Contact
-
Samsung Medical Center
RECRUITINGSeoul, 135-710, South Korea
Contact
Contact
-
Seoul National University Hospital
RECRUITINGSeoul, 110-74, South Korea
Contact
Contact
-
Seoul National University Hospital Bundang Hospital
RECRUITINGSeongnam-si, Gyeonnggi-Do, 463-707, South Korea
Contact
Contact
-
UCLA
RECRUITINGLos Angeles, California, 90095, United States
Contact
Contact
-
West Penn Allegheny Health
RECRUITINGPittsburgh, Pennsylvania, 15224, United States
Contact
Contact
-
Wisconsin Institute Medical Research- UW Cancer Connect
RECRUITINGMadison, Wisconsin, 53705, United States
Contact
Contact
-
Yonsei University Health System Severance Hospital
RECRUITINGSeoul, 03722, South Korea
Contact
Contact
Conditions
Explore the condition pages connected to this study.